Drug intelligence / Profile preview

LSI-204

Development stage: Preclinical
Lead developer: LipoSeuticals
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

LSI-204 is a lipid-based reformulation of a small molecule oncology drug currently in development by LipoSeuticals. The candidate utilizes the company's proprietary lipid delivery platform, which is engineered to enhance the solubility, stability, and pharmacokinetic profile of hydrophobic active pharmaceutical ingredients. While the specific identity of the underlying generic drug has not been publicly disclosed in high-level pipeline summaries, LSI-204 is designed for intravenous (IV) administration to treat malignant tumors. The development strategy focuses on leveraging established oncology agents to create improved therapeutic options with potentially reduced systemic toxicity or enhanced efficacy compared to standard formulations.

Beyond the preview

Go deeper on LSI-204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LSI-204.

Explore the full profile